Resilience

Resilience is a technology-focused biomanufacturing company founded in 2020. It operates a network of state-of-the-art facilities across North America - including sites in Blue Ash (its headquarters), Cincinnati, Philadelphia and Toronto - providing end-to-end development, scale-up and technology transfer for complex medicines. The company describes its mission as changing how medicines are made, with an emphasis on faster, more flexible and less risky manufacturing and on protecting supply chains against disruption.

Its technical work spans biopharmaceutical manufacturing, cell and gene therapy manufacturing, viral vector production, vaccine production and protein therapeutics, alongside process scale-up and tech transfer. The biopharmaceutical manufacturing ecosystem it has built is designed to carry programmes from development through to commercial-scale production across these modalities.

The company launched with over $800 million in capital, has secured $825 million in long-term financing, and received $410 million in funding from the U.S. Department of Defense. It operates within the biopharmaceutical, biotechnology, cell and gene therapy, vaccine, government and defence, and academic research sectors, and states a commitment to quality and reliability in serving patients.